US3755581036
© BusinessWire
09.12.2024
GILD
LISTED
NASDAQ
Kite’s Yescarta® Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024
News Preview
Kite, a Gilead Company (Nasdaq: GILD), today announced results from a five-year follow-up analysis of ZUMA-5, a Phase 2 study of Yescarta® (axicabtagene ciloleucel) in patients with relapsed/refractory non-Hodgkin lymphomas (NHL) including follicular lymphoma (FL) or marginal zone lymphoma (MZL). The analysis demonstrated that after a median follo...
Themefolio
Profiler
Peergroup
© BusinessWire
09.12.2024
GILD
LISTED
NASDAQ
Longest Follow-Up Data Reported for Kite’s Tecartus® CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits
News Preview
Kite, a Gilead Company (Nasdaq: GILD), announced results today from four analyses that continue to demonstrate the durability of response of Tecartus® (brexucabtagene autoleucel) in patients with relapsed/refractory mantle cell lymphoma (R/R MCL) and relapsed/refractory B-cell precursor acute lymphoblastic leukemia (R/R B-ALL) during the 66th Amer...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2024
GILD
LISTED
NASDAQ
Kite Presents New Data Underscoring Curative Potential of Yescarta® in Relapsed/Refractory Large B-cell Lymphoma at ASH
News Preview
Kite, a Gilead Company (Nasdaq: GILD), today announced findings from three new analyses for Yescarta® (axicabtagene ciloleucel) that demonstrate improved outcomes for people living with relapsed or refractory (R/R) large B-cell lymphoma (LBCL), which were presented at 66th American Society of Hematology (ASH) Annual Meeting & Exposition.
The...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© BusinessWire
03.12.2024
GILD
LISTED
NASDAQ
Gilead and Tubulis Enter Into Exclusive Option and License Agreement to Develop ADC Candidate for Select Solid Tumor Target
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) and Tubulis today announced that they have entered into an exclusive option and license agreement to discover and develop an antibody-drug conjugate (ADC) against a solid tumor target.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241203665344/en/...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
27.11.2024
GILD
LISTED
NASDAQ
Gilead Announces New England Journal of Medicine Publication of PURPOSE 2 Results
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) today announced The New England Journal of Medicine (NEJM) published the full results from the company’s pivotal Phase 3 PURPOSE 2 trial evaluating twice-yearly lenacapavir for the investigational use of HIV prevention among a broad and geographically diverse range of cisgender men and gender-diverse people....
Themefolio
Profiler
Peergroup
© BusinessWire
15.11.2024
GILD
LISTED
NASDAQ
Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study, which showed that 81% (30 out of 37) of participants with primary biliary cholangitis (PBC) treated with Livdelzi® (seladelpar) achieved a composite biochemical response (CBR), demonstrating significant impro...
Themefolio
Profiler
Peergroup
© BusinessWire
14.11.2024
GILD
LISTED
NASDAQ
Gilead Prices $3.5 Billion of Senior Unsecured Notes
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, today announced the pricing of senior unsecured notes in an aggregate principal amount of $3.5 billion, in an underwritten, registered public offering, consisting of $750 million of 4.80% senior not...
Themefolio
Profiler
Peergroup
© BusinessWire
13.11.2024
GILD
LISTED
NASDAQ
Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752), which is studying twice-yearly lenacapavir, the company’s injectable HIV-1 capsid inhibitor, for the investigational use of HIV prevention among a broad and geographically diverse range of cisgender m...
Themefolio
Profiler
Peergroup
© BusinessWire
12.11.2024
GILD
LISTED
NASDAQ
Scientific Leadership Spotlighted as Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new research data from its innovative HIV treatment portfolio and pipeline, including a broad range of data on investigational and marketed agents with varied dosing frequencies and administration methods. The key findings presented at the International Congress on Drug Thera...
Themefolio
Profiler
Peergroup
© BusinessWire
08.11.2024
GILD
LISTED
NASDAQ
Gilead Sciences to Present at Upcoming Investor Engagements
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:
Jefferies London Healthcare Conference on Wednesday, November 20 at 9:30 AM Greenwich Mean Time
Piper Sandler Annual Healthcare Conference on Tuesday, December 3 at 11:00 AM Eastern Time
Annual Evercore ISI HealthC...
Themefolio
Profiler
Peergroup
© BusinessWire
07.11.2024
GILD
LISTED
NASDAQ
Late-Breaking Clinical Data and Real-World Evidence Presented at HIV Glasgow as Gilead Extends Leadership Efforts Toward Ending the Epidemic
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2024), taking place from November 10-13. The results from more than 40 studies across HIV treatment and prevention include late-breaking data and seven oral presentation...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2024
GILD
LISTED
NASDAQ
Gilead Sciences Announces Third Quarter 2024 Financial Results
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its third quarter 2024 results of operations.
“Gilead’s third quarter results are the strongest of the year to date, with 7% year-over-year revenue growth, including 13% year-over-year growth for Biktarvy. Based on this very strong topline growth and disciplined operating expense management, we...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
05.11.2024
GILD
LISTED
NASDAQ
Kite to Highlight Industry-Leading CAR T-Cell Therapy Portfolio at ASH 2024, Including Positive Survival Outcomes in Both Clinical Trials and the Real-World
News Preview
Kite, a Gilead Company (Nasdaq: GILD), will share 18 presentations, including six oral presentations, demonstrating the strength of its CAR T-cell therapy portfolio across a spectrum of blood cancers during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition (December 7-10).
“Our data underscore our commitment to helping p...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
31.10.2024
GILD
LISTED
NASDAQ
AbTherx and Gilead Expand Collaboration on Innovative Antibody Discovery Technologies
News Preview
Expanded agreement includes development of additional transgenic mouse technologies and performance of additional therapeutic antibody research programs FOSTER CITY, CA / ACCESSWIRE / October 31, 2024 / AbTherx, a biotechnology company with innovative technologies that enable and accelerate therapeutic antibody discovery and development, today anno...
Themefolio
Profiler
Peergroup
© BusinessWire
22.10.2024
GILD
LISTED
NASDAQ
Gilead to Present Latest Research Across Key Liver Disease Indication at the American Association for the Study of Liver Disease (AASLD) Meeting 2024
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) today announced new research to be presented at The Liver Meeting® 2024, hosted by the American Association for the Study of Liver Diseases (AASLD) from November 15-19 in San Diego, Calif. More than 40 abstracts will be presented with key data, including 11 abstracts reporting new data on primary biliary cholan...
Themefolio
Profiler
Peergroup
© BusinessWire
19.10.2024
GILD
LISTED
NASDAQ
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new results from a Phase 2 clinical study evaluating the investigational combination of islatravir, an investigational nucleoside reverse transcriptase translocation inhibitor, and lenacapavir, a first-in-class HIV-1 ca...
Themefolio
Profiler
Peergroup
© BusinessWire
09.10.2024
GILD
LISTED
NASDAQ
Gilead Sciences to Release Third Quarter 2024 Financial Results on Wednesday, November 6, 2024
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2024 financial results and guidance will be released on Wednesday, November 6, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s third quarter 2024 financial results and provide a business up...
Themefolio
Profiler
Peergroup
© BusinessWire
09.10.2024
GILD
LISTED
NASDAQ
Gilead to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new findings from its antiviral research and development programs at IDWeek 2024, taking place from October 16-19. The data from 31 presentations across HIV treatment and prevention, COVID-19 and viral hepatitis include one late breaker abstract and six oral presenta...
Themefolio
Profiler
Peergroup
© BusinessWire
07.10.2024
GILD
LISTED
NASDAQ
Gilead Presents Additional Efficacy, Safety and Demographic Data From PURPOSE 2 Trial at 5th HIV Research for Prevention Conference
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) today announced additional data from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752) providing an overview of the efficacy and safety of twice-yearly lenacapavir, the company’s injectable HIV-1 capsid inhibitor, for the investigational use of HIV prevention among a broad and geographically diverse range of ci...
Themefolio
Profiler
Peergroup
© PR Newswire
02.10.2024
GILD
LISTED
NASDAQ
Hetero Signs Voluntary Licensing Agreement with Gilead to Transform Global HIV response, Expanding Access to Groundbreaking Lenacapavir to 120 high-incidence countries
News Preview
- Non-exclusive voluntary license agreement enables the manufacture and distribution of lenacapavir for HIV prevention and treatment of heavily treatment-experienced patients with multi drug-resistant HIV
HYDERABAD, India, Oct. 2, 2024 /PRNewswire/ -- Hetero, India's leading pharmaceutical company with the widest global reach, today announced a...
Themefolio
Profiler
Peergroup
© PR Newswire
02.10.2024
GILD
LISTED
NASDAQ
Hetero Signs Voluntary Licensing Agreement with Gilead to Transform Global HIV response, Expanding Access to Groundbreaking Lenacapavir to 120 high-incidence countries
News Preview
- Non-exclusive voluntary license agreement enables the manufacture and distribution of lenacapavir for HIV prevention and treatment of heavily treatment-experienced patients with multi drug-resistant HIV
HYDERABAD, India, Oct. 2, 2024 /PRNewswire/ -- Hetero, India's leading pharmaceutical company with the widest global reach, today announced a...
Themefolio
Profiler
Peergroup
© PR Newswire
02.10.2024
GILD
LISTED
NASDAQ
Hetero Signs Voluntary Licensing Agreement with Gilead to Transform Global HIV response, Expanding Access to Groundbreaking Lenacapavir to 120 high-incidence countries
News Preview
- Non-exclusive voluntary license agreement enables the manufacture and distribution of lenacapavir for HIV prevention and treatment of heavily treatment-experienced patients with multi drug-resistant HIV
HYDERABAD, India, Oct. 2, 2024 /PRNewswire/ -- Hetero, India's leading pharmaceutical company with the widest global reach, today announced a...
Themefolio
Profiler
Peergroup
© BusinessWire
02.10.2024
GILD
LISTED
NASDAQ
Gilead Signs Royalty-Free Voluntary Licensing Agreements With Six Generic Manufacturers to Increase Access to Lenacapavir for HIV Prevention in High-Incidence, Resource-Limited Countries
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has signed non-exclusive, royalty-free voluntary licensing agreements with six pharmaceutical manufacturers to make and sell generic lenacapavir, subject to required regulatory approvals, in 120 high-incidence, resource-limited countries, which are primarily low- and lower-middle income...
Themefolio
Profiler
Peergroup
© BusinessWire
12.09.2024
GILD
LISTED
NASDAQ
Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 Trial
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the results of an interim analysis from a second pivotal Phase 3 clinical trial investigating the use of the company’s twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir. Lenacapavir reduced HIV infections by 96% compared to background HIV incidence (bHIV). There were 2 incident cases a...
Themefolio
Profiler
Peergroup
© BusinessWire
10.09.2024
GILD
LISTED
NASDAQ
Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) and Genesis Therapeutics, Inc. announced today that the companies have entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240910912771...
Themefolio
Profiler
Peergroup
© BusinessWire
05.09.2024
GILD
LISTED
NASDAQ
Gilead to Present New Trodelvy® Data at the IASLC 2024 World Conference on Lung Cancer
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) will present new data from the company’s broad lung cancer clinical development program during the IASLC 2024 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer, taking place Sept. 7-10, 2024 in San Diego, Calif. Data to be highlighted across three oral presenta...
Themefolio
Profiler
Peergroup
© BusinessWire
21.08.2024
GILD
LISTED
NASDAQ
Gilead Sciences to Present at Upcoming Investor Conferences
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:
Wells Fargo Healthcare Conference on Wednesday, September 4 at 11:00 AM Eastern Time
Morgan Stanley Annual Global Healthcare Conference on Thursday, September 5 at 12:20 PM Eastern Time
Baird Global Healthcare...
Themefolio
Profiler
Peergroup
© BusinessWire
14.08.2024
GILD
LISTED
NASDAQ
Gilead’s Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Livdelzi® (seladelpar) for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have had an inadequate response to UDCA, or as monotherapy in patients...
Themefolio
Profiler
Peergroup
© BusinessWire
08.08.2024
GILD
LISTED
NASDAQ
Gilead Sciences Announces Second Quarter 2024 Financial Results
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its second quarter 2024 results of operations.
“Gilead has had another strong quarter with 6% year-over-year growth in our base business. This was driven by sales of our therapies for HIV, Oncology and Liver Disease, including 8% growth for Biktarvy,” said Daniel O’Day, Gilead’s Chairman and C...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
